Severe acute respiratory syndrome–related coronavirus

CURIS System Wins METRO'S Innovative Solutions Award for Fight Against COVID on Buses & Motorcoaches

Thursday, October 29, 2020 - 3:00pm

OVIEDO, Fla., Oct. 29, 2020 /PRNewswire-PRWeb/ -- CURIS System is proud to announce today that is has been awarded the 2020 Innovative Solutions Award for Safety by METRO Magazine for its pulse fogging system that fights SARS-CoV-2 (COVID-19).

Key Points: 
  • OVIEDO, Fla., Oct. 29, 2020 /PRNewswire-PRWeb/ -- CURIS System is proud to announce today that is has been awarded the 2020 Innovative Solutions Award for Safety by METRO Magazine for its pulse fogging system that fights SARS-CoV-2 (COVID-19).
  • When the novel coronavirus hit the transportation industry, some companies scrambled to find solutions to help keep drivers safe and routes operational.
  • "Adding the CURIS fogging system as a part of our sanitizing protocols provides us with a gold standard solution for the COVID-19 era."
  • The CURIS Decontamination System is designed to effectively work in such environments as:

Viral 'molecular scissor' is next COVID-19 drug target: Coronavirus uses enzymatic cutter for virus production and to disable essential immune proteins

Sunday, October 18, 2020 - 12:10pm

The researchers are from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and the Wroclaw University of Science and Technology.

Key Points: 
  • The researchers are from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and the Wroclaw University of Science and Technology.
  • Information gleaned by the American team helped Polish chemists to develop two molecules that inhibit the cutter, an enzyme called SARS-CoV-2-PLpro.
  • "It stimulates the release of proteins that are essential for the virus to replicate, and it also inhibits molecules called cytokines and chemokines that signal the immune system to attack the infection," Dr. Olsen said.
  • Visit our online Newsroom , and to see how we are battling COVID-19, read inspiring stories on Impact .

Congenica Launches New Host Genetics Module to Advance COVID-19 Research

Tuesday, September 22, 2020 - 1:00pm

Initial studies indicate a variety of factors socioeconomics, pre-existing medical conditions and genetics all play their part.

Key Points: 
  • Initial studies indicate a variety of factors socioeconomics, pre-existing medical conditions and genetics all play their part.
  • Research studies are providing evidence of the importance of specific variations in host genes related to SARS-CoV-2 viral entry, viral replication, and immune response.
  • The launch of the Congenica COVID-19 module, available within the company's genomic analysis software platform, will enable researchers to focus analysis on the host genetics that underpin COVID-19 infection using high-quality sets of relevant genes.
  • Congenica software is for research use only and should not be used as a diagnostic tool.

Congenica Launches New Host Genetics Module to Advance COVID-19 Research

Tuesday, September 22, 2020 - 8:00am

Initial studies indicate a variety of factors socioeconomics, pre-existing medical conditions and genetics all play their part.

Key Points: 
  • Initial studies indicate a variety of factors socioeconomics, pre-existing medical conditions and genetics all play their part.
  • Research studies are providing evidence of the importance of specific variations in host genes related to SARS-CoV-2 viral entry, viral replication, and immune response.
  • The launch of the Congenica COVID-19 module, available within the company's genomic analysis software platform, will enable researchers to focus analysis on the host genetics that underpin COVID-19 infection using high-quality sets of relevant genes.
  • Congenica software is for research use only and should not be used as a diagnostic tool.

SARS-CoV-2 Whole Virus & Full Process IVD Controls Join Microbiologics' Extensive Line of Standards

Thursday, September 10, 2020 - 12:53pm

Offering a comprehensive portfolio of SARS-CoV-2 molecular QC standards, Microbiologics is launching IVD Process Controls and Inactivated Whole Virus Controls to meet the complex research and diagnostic challenges of the COVID-19 pandemic.

Key Points: 
  • Offering a comprehensive portfolio of SARS-CoV-2 molecular QC standards, Microbiologics is launching IVD Process Controls and Inactivated Whole Virus Controls to meet the complex research and diagnostic challenges of the COVID-19 pandemic.
  • The Inactivated Whole Virus Controls contain the entire SARS-CoV-2 genome in a non-infectious state confirmed by a validated assay.
  • The synthetic RNA within the Process Controls is encapsulated in a phage protein envelope to validate the extraction process.
  • These new controls join the most comprehensive line of SARS-CoV-2 QC and research materials in the world.

QIAGEN Expands Integrated Coronavirus NGS and Software Solutions to Accelerate COVID-19 Research

Tuesday, August 18, 2020 - 9:05pm

These solutions aim to accelerate research into COVID-19 prevention and treatment by enabling deeper, more holistic insights into the biology of SARS-CoV-2.

Key Points: 

Bio-Techne Announces Release of a New SARS-CoV-1/2 Spike RBD LlaMABody™ Recombinant Antibody that Blocks Viral Entry

Tuesday, August 11, 2020 - 12:00pm

MINNEAPOLIS, Aug. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SARS-CoV-2 spike receptor binding domain (RBD) and blocks the virus from binding to its host receptor, ACE-2, inhibiting viral infection .

Key Points: 
  • MINNEAPOLIS, Aug. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SARS-CoV-2 spike receptor binding domain (RBD) and blocks the virus from binding to its host receptor, ACE-2, inhibiting viral infection .
  • The SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody is the first camelid antibody offering in our new LlaMABody product line.
  • This antibody reflects Bio-Techne's well-established expertise in recombinant antibody engineering as a growing segment in our business, especially in biopharma.
  • "This new SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody is just part of a growing portfolio of tools from Bio-Techne that support SARS-CoV-2 research, diagnostics and therapeutic development."